SMMT Summit Therapeutics Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2015

Commission File Number 001-36866

SUMMIT THERAPEUTICS PLC

(Translation of registrant’s name into English)

85b Park Drive

Milton Park, Abingdon

Oxfordshire OX14 4RY

United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F  x            FORM 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

YES  ¨            NO   x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):            

On June 17, 2015, Summit Therapeutics plc (the “Company”) issued a press release announcing that it had granted share options to certain executive and non-executive directors, officers and other members of the Company under its Share Option Plan. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

On June 17, 2015, the Company announced details of purchases of the Company’s American Depositary Shares (“ADSs”) by Dr Frank Armstrong, Non-Executive Chairman of the Company. The press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

The information contained in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 17, 2015

EXHIBIT INDEX

Exhibit 99.1

Summit Therapeutics plc

(“Summit” or the “Company”)

AWARD OF SHARE OPTIONS

Oxford, UK, 17 June 2015 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that on 16 June 2015 it granted Share Options over 2,422,333 ordinary shares of 1p nominal value (‘Shares’) to Executive and Non-Executive Directors and Officers, and other members of the Company under the existing Company Share Option Plan at an exercise price of 143 pence per Share (being the mid-market closing price of a Summit ordinary share on 15 June 2015).

The details of the award to Executive and Non-Executive Directors and Officers are as follows:

All the options will vest fully on 16 June 2018 subject to the average closing ordinary share price being equal to or greater than 214.5 pence in any period of 30 consecutive calendar days ending on or before that date. The options will lapse if this performance condition is not met by 16 June 2018.

This share option award forms an important part of the strategy to retain and motivate people who will be key to the success of the Company. The Board believes this award is aligned with the interests of all shareholders as the Company seeks to generate long-term shareholder value.

Post these grants the Executive and Non-Executive Directors and Officers hold the following options in aggregate:

- END -

For more information, please contact:

Exhibit 99.2

Summit Therapeutics plc

(“Summit” or the “Company”)

DIRECTOR SHARE DEALING

Oxford, UK, 17 June 2015 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that the Company has been notified that Dr Frank Armstrong, Non-Executive Chairman of the Company, has on 16 June 2015 bought 850 American Depositary Shares (‘ADSs’) of Summit at an average price of $11.70 per ADS.

Following this notification Dr Armstrong’s beneficial interest in Summit Shares is 10,192 ordinary shares of 1 pence nominal value and 850 ADSs, representing approximately 0.02% of the Company’s current issued share capital. The ADSs were acquired on the NASDAQ Global Market.

This notification relates to disclosures made in accordance with Rule 17 Schedule 5 of the AIM Rules.

- END -

For more information, please contact:

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024